23 May 2022 in Nature Communications
Muscarinic acetylcholine receptors (mAChRs) respond to the neurotransmitter acetylcholine and play important roles in human nervous system. Muscarinic receptor 4 (M4R) is a promising drug target for treating neurological and mental disorders, such as Alzheimer’s disease and schizophrenia. However, the lack of understanding on M4R’s activation by subtype selective agonists hinders its therapeutic applications. Here, we report the structural characterization of M4R selective allosteric agonist, compound-110, as well as agonist iperoxo and positive allosteric modulator LY2119620. Our cryo-electron microscopy structures of compound-110, iperoxo or iperoxo-LY2119620 bound M4R-Gi complex reveal their different interaction modes and activation mechanisms of M4R, and the M4R-ip-LY-Gi structure validates the cooperativity between iperoxo and LY2119620 on M4R. Through the comparative structural and pharmacological analysis, compound-110 mostly occupies the allosteric binding pocket with vertical binding pose. Such a binding and activation mode facilitates its allostersic selectivity and agonist profile. In addition, in our schizophrenia-mimic mouse model study, compound-110 shows antipsychotic activity with low extrapyramidal side effects. Thus, this study provides structural insights to develop next-generation antipsychotic drugs selectively targeting on mAChRs subtypes.
29 August 2022 in Angewandte Chemie International Edition
1 February 2008 in Key Engineering Materials
(1-X)BaTiO3-XCaCu2.94Mn0.06Ti4O12 (BTO-CCMTO) composite ceramics with X =0.1 and 0.2 were prepared through solid state reaction route. X-ray diffraction (XRD) analyses showed that a co-existence structure of BTO and CCMTO phase can be realized when the sample was sintered at 950°C. Furthermore, influences of CCMTO on the dielectric behaviors of the BTO-CCMTO composite ceramics were investigated. The results showed that the dielectric permittivity of the BTO-CCMTO composite ceramics increases with increasing amounts of CCMTO and the Curie peak of the pure BTO ceramics is greatly suppressed due to the addition of CCMTO. The dielectric loss of the BTO-CCMTO composite ceramics can be kept in the same magnitude order as that of the BTO ceramics.
29 August 2022 in Angewandte Chemie
21 September 2026 in Research Square
Neuroinflammation and tau aggregation are hallmarks of Alzheimer’s disease (AD), yet the mechanistic link between them remains unknown. Analyzing a cohort of 46 AD and 40 control subjects using mass spectrometry-based proteomics, we identified a strong correlation between upregulation of the cytokine-induced antigen-presentation pathway and site-specific tau cleavage. This cleavage enriches the microtubule-binding repeat (MTBR) domain in AD tau aggregates; furthermore, synthetic MTBR fragments recapitulate tau aggregation both in vitro and in vivo. Our data show that the immunoproteasome (IP) colocalizes with tau aggregates in human AD neurons and drives the observed cleavage pattern. Proinflammatory cytokines reproduced AD-like tau cleavage and puncta formation in HEK293T cells expressing 0N4R tau, the hTau knock-in mouse, and human iPSC-derived neurons (iNeurons). IP knockdown via siRNA reduced tau-positive inclusion and upstream JAK/STAT pathway inhibition across model systems, including iNeurons, effectively abrogated cleavage and tau aggregation. These findings identify an inflammation-responsive pathway that promotes tau pathology and provide a mechanistic framework and potential therapeutic entry point for AD and potentially other tauopathies.